Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Latest Information Update: 06 Mar 2023
At a glance
- Drugs Fibroblast growth factor 1 (Primary)
- Indications Coronary artery disease; Ischaemic heart disorders
- Focus Therapeutic Use
- Acronyms ACORD
- Sponsors Venturis Therapeutics
- 26 Apr 2019 Planned End Date changed from 15 Oct 2022 to 1 Mar 2023.
- 26 Apr 2019 Planned End Date changed from 15 Oct 2022 to 1 Mar 2023.
- 26 Apr 2019 Planned primary completion date changed from 15 Oct 2021 to 1 Mar 2022.